REGENXBIO Inc. (NASDAQ:RGNX), a biotechnology company specializing in gene therapy development, stands at a pivotal juncture in its journey to bring innovative treatments to market. With a focus ...

Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...

周四，H.C. Wainwright将NASDAQ:RGNX，即Regenxbio Inc.的目标价从此前的$40下调至$36，同时重申对该股票的买入评级。这一调整是在该公司发布了一项针对杜氏肌营养不良症 (DMD)治疗的早期临床试验的有希望的功能数据之后做出的。

RGX-202是一种潜在“best-in-class”的基因疗法，旨在改善杜氏肌营养不良症患者的肌肉功能和预后。RGX-202的独特之处在于编码的微抗肌萎缩蛋白中包含了关键的C末端（CT）结构域，在临床前研究中，CT结构域已被证明可保护肌肉免受收缩引起的压力并改善其自我修复能力。

Quest Partners LLC reduced its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 42.7% in the third quarter, according to the company in its most recent 13F filing with the Securities ...

Based on a small trial with positive muscle performance data, Regenxbio is expected to pursue approval of its gene therapy ...

周五，Morgan Stanley恢复了对Regenxbio Inc. (NASDAQ:RGNX)股票的覆盖，给予超配评级，目标价为22.00美元。 该公司的分析认识到基因疗法在治疗VEGF介导疾病方面的潜力，这些疾病目前存在较高的未满足医疗需求。然而，分析师也对商业可行性表示谨慎，因为视网膜下给药方法存在挑战。 分析师指出，虽然Regenxbio的RGX-314脉络膜上腔给药的数据仍处于初步阶段 ...

Regenxbio has revealed plans to submit a biologics licence application (BLA) for RGX-202, its investigational gene therapy ...

H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Regenxbio (RGNX) to $36 from $40 and keeps a Buy rating on the shares after ...

Across the recent three months, 5 analysts have shared their insights on Regenxbio RGNX, expressing a variety of opinions ...

Regenxbio hopes to use the study's results to ask the U.S. Food and Drug Administration to grant accelerated approval to the ...

Morgan Stanley assumed coverage of Regenxbio (RGNX) with an Overweight rating and $22 price target The firm appreciates the attractiveness of ...